Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Structure-based strategies for drug design and discovery.

Kuntz ID.

Science. 1992 Aug 21;257(5073):1078-82. Review.

PMID:
1509259
2.

Importance of molecular computer modeling in anticancer drug development.

Geromichalos GD.

J BUON. 2007 Sep;12 Suppl 1:S101-18. Review.

PMID:
17935268
3.

[Development of new enzyme inhibitors for the treatment of AIDS[ ].

Herdewijn P.

Verh K Acad Geneeskd Belg. 1992;54(2):139-53. Dutch.

PMID:
1384252
4.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
5.

Development of antiviral drugs for the treatment of AIDS: strategies and prospects.

Haseltine WA.

J Acquir Immune Defic Syndr. 1989;2(4):311-34. Review.

PMID:
2666638
6.

New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent.

Hausheer FH, Kochat H, Parker AR, Ding D, Yao S, Hamilton SE, Petluru PN, Leverett BD, Bain SH, Saxe JD.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S3-15. Review.

PMID:
12819940
7.

Discovery and in vitro development of AIDS antiviral drugs as biopharmaceuticals.

Rice WG, Bader JP.

Adv Pharmacol. 1995;33:389-438. Review.

PMID:
7495676
8.

Molecular targets for AIDS therapy.

Mitsuya H, Yarchoan R, Broder S.

Science. 1990 Sep 28;249(4976):1533-44. Review.

PMID:
1699273
9.

Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction.

Sillerud LO, Larson RS.

Curr Protein Pept Sci. 2005 Apr;6(2):151-69. Review.

PMID:
15853652
10.

The 3-D structure of HIV-1 proteinase and the design of antiviral agents for the treatment of AIDS.

Blundell TL, Lapatto R, Wilderspin AF, Hemmings AM, Hobart PM, Danley DE, Whittle PJ.

Trends Biochem Sci. 1990 Nov;15(11):425-30. Review.

PMID:
2278102
11.

New strategies for treating AIDS.

Sandstrom PA, Folks TM.

Bioessays. 1996 May;18(5):343-6. Review.

PMID:
8639156
12.

Rational drug design: the proteinase inhibitors.

Wlodawer A.

Pharmacotherapy. 1994 Nov-Dec;14(6 Pt 2):9S-20S.

PMID:
7885983
13.

Structure-based inhibitor design.

Craig SP 3rd, Eakin AE.

Vitam Horm. 2000;58:149-69. Review.

PMID:
10668398
14.

Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.

Lu H, Tonge PJ.

Acc Chem Res. 2008 Jan;41(1):11-20. doi: 10.1021/ar700156e. Review.

PMID:
18193820
15.

Inhibitors of HIV-1 reverse transcriptase and integrase: classical and emerging therapeutical approaches.

Tarrago-Litvak L, Andreola ML, Fournier M, Nevinsky GA, Parissi V, de Soultrait VR, Litvak S.

Curr Pharm Des. 2002;8(8):595-614. Review.

PMID:
11945161
16.

Cancer Drug Development: New Targets for Cancer Treatment.

Curt GA.

Oncologist. 1996;1(3):II-III.

PMID:
10387987
17.

HIV-1 integrase: the next target for AIDS therapy?

d'Angelo J, Mouscadet JF, Desmaƫle D, Zouhiri F, Leh H.

Pathol Biol (Paris). 2001 Apr;49(3):237-46. Review.

PMID:
11367559
18.

Strategies for indirect computer-aided drug design.

Loew GH, Villar HO, Alkorta I.

Pharm Res. 1993 Apr;10(4):475-86. Review.

PMID:
8483829
19.

Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.

Tsantrizos YS.

Acc Chem Res. 2008 Oct;41(10):1252-63. doi: 10.1021/ar8000519.

PMID:
18681464
20.

New developments in diketo-containing inhibitors of HIV-1 integrase.

Zhao G, Wang C, Liu C, Lou H.

Mini Rev Med Chem. 2007 Jul;7(7):707-25. Review.

PMID:
17627583
Items per page

Supplemental Content

Support Center